X

Drug Profile

Probucol - Aventis

Alternative Names: DE 3872; Sinlestal

Latest Information Update: 25 Sep 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aventis
Developer Daiichi Pharmaceutical
Class Antihyperlipidaemics; Phenols
Mechanism of Action Antioxidants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Coronary artery restenosis

Most Recent Events

10 Jan 2001 Discontinued-III for Coronary artery restenosis in Canada (PO)
10 Jan 2001 Discontinued-III for Coronary artery restenosis in Japan (PO)
22 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com